Sponsored by

PuffItUp Dynavap VGoodiez 420EDC
  • Welcome to VaporAsylum! Please take a moment to read our RULES and introduce yourself here.
  • Need help navigating the forum? Find out how to use our features here.
  • Did you know we have lots of smilies for you to use?

momofthegoons

Vapor Accessory Addict
Staff member
Clinical Trials of Cannabinoids – 4Q 2017 Report

In this update: OCD, pancreatic cancer, osteoarthritis, bipolar, depression/anxiety, dementia, lupus, vascular function, & multiple sclerosis.


New Study Starts (4Q 2017):

1. Effects of Marijuana on Symptoms of OCD
Obsessive-compulsive disorder (OCD) is “a common, chronic and long-lasting disorder in which a person has uncontrollable, reoccurring thoughts (obsessions) and behaviors (compulsions) that he or she feels the urge to repeat over and over.”

The purpose of this pilot research study is to test whether cannabinoids, may help to reduce symptoms in patients with OCD. Patient will be randomized to one of 3 arms:

    • Placebo control
    • Low THC / high CBD cannabis
    • High THC / low CBD cannabis
This study is sponsored by New York State Psychiatric Institute and primary study completion is expected in October, 2018.

2. The Effect of Cannabis in Pancreatic Cancer
The prevalence of malnutrition is overwhelming in pancreatic cancer patients, with over 80% of patients experiencing significant weight loss.

The purpose of this clinical trial is to examine the effects of the cannabinoids THC and CBD on energy- and protein intake and lean body mass as a measure of appetite, nausea and quality of life. Patients will be randomized to one of 2 arms:

    • No treatment (control)
    • THC/CBD oral drops (1:2 ratio) individually dose titrated
This study is sponsored by University of British Columbia and primary study completion is expected in July, 2019.

3. Maximizing Analgesia to Reduce Pain in Knee Osteoarthritis
Osteoarthritis occurs when the protective cartilage on the ends of your bones wears down over time. It affects millions of people wordwide.

This study will evaluate whether a combination of pharmacotherapies can effectively alleviate osteoarthritis knee pain. Drugs that will be tested alone and in combination include:

    • Prescription stimulants
    • Prescription benzodiazepines
    • Prescription opioids
    • Prescription cannabinoids
    • Over-the-counter medications
    • Placebo
This study is sponsored by Johns Hopkins University and primary study completion is expected in June, 2020.

4. Cannabidiol as an Adjunctive Treatment for Bipolar Depression
Bipolar disorder is a brain disorder that involves clear changes in mood, energy, and activity levels. These moods range from periods of extremely “up,” elated, and energized behavior (known as manic episodes) to very sad, “down,” or hopeless periods (known as depressive episodes).

The purpose of this study is to examine whether treatment with cannabidiol (CBD) will result in improvement of depressive and anxiety symptoms, as well as improvement in functioning and inflammatory biomarkers. Patients will be randomized to one of 2 groups:

    • Placebo
    • Cannabidiol (oral, 600 mg/day)
This study is sponsored by Hospital de Clinicas de Porto Alegre (Brazil) and primary study completion is expected in October, 2019.

5. Study of Dronabinol Treatment for Depression and/or Anxiety in Older Patients
Anxiety and depression are common conditions in older patients.

Dronabinol is a synthetic version of THC that is approved by the FDA.

The purpose of this observational study is to better understand how effective dronabinol treatment is when prescribed for depression and/or anxiety in older patients. The investigators also want to find out if dronabinol is safe to take in this older population without causing too many side effects.

This study is sponsored by Mclean Hospital and primary study completion is expected in January, 2019.

6. The Effect of Cannabis on Dementia Related Agitation and Aggression
The most common syndrome in patients with severe dementia is agitated behavior, which is often characterized by a combination of violent behavior (physical or verbal), restlessness, and inappropriate loudness. The treatment options for this syndrome are limited and lead to severe side effects.

The purpose of this study is to evaluate whether cannabis oil can benefit these symptoms in elderly patients with dementia and provide a higher quality of life. Patients will be randomized to one of 2 treatment arms:

    • Placebo oil
    • Cannabis oil containing a CBD:THC ratio of 20:1.
This study is sponsored by TO Pharmaceuticals and primary study completion is expected in November, 2019.

Read about more studies on the topic of using cannabinoids to treat the behavioral effects of dementia.

7. JBT-101 in Systemic Lupus Erythematosus
Systemic lupus erythematosus (SLE) is an autoimmune disease that can affect the skin, joints, kidneys, brain, and other organs.

JBT-101 (also called lenabasum) is a synthetic cannabinoid CB2 receptor agonist with anti-fibrotic and anti-inflammatory effects.

The objective of this study is to evaluate the efficacy, safety, and tolerability of JBT-101 in systemic lupus erythematosus (SLE) patients.

This study is sponsored by National Institute of Allergy and Infectious Diseases and primary study completion is expected in February, 2020.

8. Cannabinoid Supplementation on Vascular and Cognitive Function
The purpose of this study is to improve our understanding of how CBD might control and regulate blood vessel health as well as cognitive and exercise performance. Healthy volunteers will receive 5 different treatments in different periods of the study:

    • Placebo control
    • Oral CBD (low dose)
    • Oral CBD (high dose)
    • Oral CBD supplemented with ginseng, ginkgo biloba, and organic hemp oil (low dose)
    • Oral CBD supplemented with ginseng, ginkgo biloba, and organic hemp oil (high dose)
This study is sponsored by University of British Columbia and primary study completion is expected in July, 2019.

Study Completions (4Q 2017):

1. Medical Marijuana and Its Effects on Motor Function in People With Multiple Sclerosis
Multiple sclerosis (MS) is a disabling disease of the brain and spinal cord where the immune system attacks the protective sheath that covers nerve fibers. Medical cannabis is commonly prescribed to MS patients for muscle spasticity and pain. However, the effects of medical cannabis have not been well characterized on measures of physical functioning, such as fatigue, strength and walking ability.

The purpose of this study is to investigate the effects of medical cannabis on physical functioning using an observational case-control design that compares medical cannabis users to matched control non-cannabis users.

This study is sponsored by Colorado State University and primary study completion was in October, 2017.

See prior report: Clinical Trials of Cannabinoids – 3Q 2017

All information is from ClinicalTrials.gov. Not every trial related to cannabinoids is featured, just selected ones that highlight the therapeutic potential of cannabinoids.
 

Sponsored by

PuffItUp Dynavap VGoodiez 420EDC
Top